■2013年批准了直接作用抗病毒(DAA)方案,其反应率超过95%,副作用最小。sofosbuvir和ledipasvir的反应率超过95%,副作用最小。
■为了确定该方案在根除患者病毒中的作用。材料和方法:前瞻性观察,开放标签研究于2018年7月至2020年9月期间进行.该研究包括37名患者,其中约三分之二为男性23(62.16%),而女性为14人(37.84%)。所有患者均根据其体重以单次口服每日剂量接受索非布韦400mg和ledipasvir90mg的组合。
■最常见的HCV基因型是HCV-4,其次是HCV-1和HCV-2。通过比较基线参数,治疗结束,完成治疗后12周,实验室数据显示所有肝功能检查都急剧下降,丙氨酸氨基转移酶(ALT)的平均值(31.1±1.42IU/lvs.95.5±23.16,p<0.05),天冬氨酸转氨酶(AST)(29.86±1.75IU/lvs.89.19±24.83,p<0.05),血清总胆红素(TSB)(0.57±0.07mg/dlvs.1.73±0.38mg/dl,p<0.05),平均HCVPCR(1605168±368223.72),疗程结束后,12周后检测不到(p<0.05)。
■在感染慢性HCV感染的伊拉克儿童和青少年中,使用剂量调整的口服DAAs(SOF/LED)治疗12周的耐受性良好,成功率高,副作用小。
UNASSIGNED: Direct-acting antiviral (DAA) regimens were approved in 2013 with a response rate exceeding 95% and minimal side effects. The response rate of sofosbuvir and ledipasvir exceeds 95% with minimal side effects.
UNASSIGNED: To identify the effects of this regimen in the eradication of viruses from the patients.Material and methods: A prospective observational, open-label study took place between July 2018 and September 2020. The study included 37 patients, about two-thirds of them were male 23 (62.16%), while females comprised 14 (37.84%). All patients received a combination of sofosbuvir 400 mg and ledipasvir 90 mg in a single oral daily dose according to their weight.
UNASSIGNED: The most common HCV genotype was HCV-4, followed by HCV-1 and HCV-2. And by comparing parameters at baseline, end of the treatment, and 12 weeks after completing the treatment, the laboratory data revealed dramatic drops of all liver function tests, the mean of alanine aminotransferase (ALT) (31.1 ±1.42 IU/l vs. 95.5 ±23.16, p < 0.05), aspartate aminotransferase (AST) (29.86 ±1.75 IU/l vs. 89.19 ±24.83, p < 0.05), total serum bilirubin (TSB) (0.57 ±0.07 mg/dl vs. 1.73 ±0.38 mg/dl, p < 0.05), mean HCV PCR (1605168 ±368223.72), after finishing the treatment course, and 12 weeks after that it was non-detectable (p < 0.05).
UNASSIGNED: Treatment with dose-adjusted oral DAAs (SOF/LED) for 12 weeks was well tolerated in Iraqi children and adolescents infected with chronic HCV infections, with a high success rate and trivial adverse effects.